FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)

XARELTO® is the only Factor Xa inhibitor to demonstrate superior efficacy in reducing the continued risk of recurrent VTE after initial treatment and with major bleeding rates similar to aspirin Phase 3 EINSTEIN CHOICE study shows XARELTO® 10 mg... Biopharmaceuticals, FDA Janssen Pharmaceuticals, XARELTO, rivaroxaban, Venous Thromboembolism
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news